CVRx

CVRX · NASDAQ

$1.39+$0.04 (+2.96%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.35

CVRX analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $4.39 (+215.5% upside)

Low: $3.54
Now: $1.39
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

CVRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Aug 17, 2026	Maintains	Overweight	$13.00 → $5.00	34%
Lake Street	Aug 7, 2026	Downgrade	Buy → Hold	$14.00 → $3.50	36%
Canaccord Genuity	Apr 14, 2026	Maintains	Buy	$10.00	44%
Canaccord Genuity	Feb 13, 2026	Maintains	Buy	$11.00 → $10.00	44%
Canaccord Genuity	Nov 6, 2025	Maintains	Buy	$9.00 → $11.00	44%
Cantor Fitzgerald	Nov 6, 2025	Maintains	Overweight	$11.00 → $13.00	32%

The case for and against

Updated Aug 4, 2026

Bull case

CVRx is a commercial-stage medical device company with a proprietary platform technology, Barostim, designed to treat cardiovascular diseases by leveraging the power of the brain to address the imbalance of the Autonomic Nervous System. Despite a slight decrease in active accounts in Q4/26, the company expects to add approximately three territories per quarter and grow net accounts in the high single digits. Additionally, the recent implementation of Category I CPT codes should reduce reimbursement friction and improve commercial access, which could expand the total addressable market for Barostim. Overall, with strong financial results and market potential, we maintain a positive outlook on CVRx's stock.

Bear case

CVRx is seeing revenue growth and gross margin outperform their initial 2026 projections. However, the company's Q1 OpEx was higher than expected, and their number of active sites is slightly lower than anticipated. There is potential for future growth with the BENEFIT-HF trial, but current productivity levels and a decline in the company's comparative multiple lead to a lowered price target of $10.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.